TICKERNERD
Menu
ABBVABBVHealthcare · Drug Manufacturers - General

ABBV Stock Forecast: AbbVie, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$265
+1.20% on the day

The 31 Wall Street analysts covering AbbVie, Inc. hold a median 12-month price target of $280 — +5.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 96 of 100 as at 22 Aug 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$468.2B
Ticker Nerd rank
96 / 100
Median analyst target
$280
Analysts covering
31
Total return, dividends reinvested
1W
+6.2%
1M
+3.5%
YTD
+18.7%
1Y
+30.4%
From 52W high
−0.4%
From 52W low
+35.2%
$196
$266
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ABBV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores AbbVie, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
96 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
100
Accruals
90
Value
88
Quality
86
Momentum
83
Growth
80
Revisions
73
Issuance
60
Size
0

Volatility (100): The share price has been relatively steady.

Issuance (60): The company has been issuing shares or taking on financing, diluting existing holders.

Size (0): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ABBV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ABBV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Oct 25Jan 26Apr 26Jul 26ABBVHigh $328Median $280Low $200

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says31 analysts
25 Buy5 Hold1 Sell
Low $200Median $280High $328

The green dot is the last close — the median target sits +5.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
17 Aug 2026Wells FargoMaintainsOverweight$295 → $300
13 Aug 2026Wolfe ResearchUpgradeOutperform$300
11 Aug 2026BNP ParibasMaintainsNeutral$218 → $247
10 Aug 2026Evercore ISI GroupMaintainsOutperform$246 → $260
4 Aug 2026GuggenheimMaintainsBuy—
4 Aug 2026GuggenheimMaintainsBuy$261 → $288
3 Aug 2026Canaccord GenuityMaintainsBuy$282 → $290
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Cantor FitzgeraldMaintainsOverweight$265 → $285
3 Aug 2026Cantor FitzgeraldMaintainsOverweight—
29 July 2026BarclaysMaintainsOverweight$275 → $300
29 July 2026BarclaysMaintainsOverweight—
22 July 2026Canaccord GenuityMaintainsBuy$273 → $282
22 July 2026Canaccord GenuityMaintainsBuy—
15 July 2026CitigroupMaintainsNeutral$230 → $260
15 July 2026CitigroupMaintainsNeutral—
13 July 2026BMO CapitalMaintainsOutperform—
13 July 2026BMO CapitalMaintainsOutperform$258 → $300
13 July 2026UBSMaintainsNeutral—
13 July 2026UBSMaintainsNeutral$230 → $260

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ABBV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

ABBV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−1.6%
Analysts raising
0
Analysts cutting
16
Fundamentals

AbbVie, Inc. (ABBV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
75.1×

Cheaper than 10% of US stocks

Price / sales
7.3×

Cheaper than 18% of US stocks

Price / book
−79.6×

Cheaper than 99% of US stocks

EV / EBITDA
17.1×

Cheaper than 20% of US stocks

Growth & margins
Revenue growth (YoY)
10.2%

Higher than 53% of US stocks

Earnings growth (YoY)
285.2%

Higher than 92% of US stocks

Gross margin
74.7%

Higher than 87% of US stocks

Operating margin
40.0%

Higher than 92% of US stocks

Net margin
9.8%

Higher than 69% of US stocks

Returns & dividend
Return on equity
−129.7%

Higher than 11% of US stocks

Return on assets
10.5%

Higher than 93% of US stocks

Dividend yield
2.6%

Higher than 58% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ABBV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
ABBVAbbVie, Inc.$468.2B
96
MRKMerck & Co., Inc.$378.6B
83
JNJJohnson & Johnson$650.8B
92
AMGNAmgen, Inc.$236.8B
92
LLYEli Lilly & Co.$1.2T
91
GILDGilead Sciences, Inc.$181.4B
92
PFEPfizer Inc.$159.6B
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own AbbVie, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ABBV news & analysis

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

PRNewsWire · 21 Aug 2026positive

AbbVie announced it will present new clinical data at the 2026 World Conference on Lung Cancer (WCLC), including an oral presentation of its ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in frontline non-small cell lung cancer, along with updates from its telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer.

Why it matters — The presentations showcase the breadth of AbbVie's lung cancer pipeline, spanning next-generation immunotherapies, targeted antibody-drug conjugates, and potential combination approaches, offering watchers visibility into the company's oncology strategy and clinical progress.

Dividend Giants Pfizer, Chevron, AbbVie: Bold 2027 Price Targets Ahead

24/7 Wall Street · 20 Aug 2026positive

The article highlights dividend giants, noting AbbVie has added 19.16% year to date in 2026, and discusses bold 2027 price targets for these companies including Pfizer and Chevron.

Why it matters — An AbbVie watcher would care because the piece positions ABBV as a strong performer among major dividend payers and signals analyst attention on its 2027 price outlook.

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

PRNewsWire · 18 Aug 2026positive

AbbVie announced that 34 students living with inflammatory conditions such as atopic dermatitis, psoriasis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis will receive the 2026 AbbVie Immunology Scholarship. The announcement marks the program's 10th year, noting that since its 2016 launch it has supported hundreds of students and is now renewable for up to four years.

Why it matters — AbbVie watchers would care because the milestone reflects the company's sustained decade-long patient-community engagement across its core immunology franchise.

Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year

The Motley Fool · 16 Aug 2026positive

AbbVie's neuroscience segment has become a second major growth engine, with revenue in that segment growing 20% in the latest quarter. Management now projects $12.7 billion in neuroscience sales for this year.

Why it matters — AbbVie watchers would care because neuroscience is emerging as a significant new pillar of growth beyond the company's core business.

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 14 Aug 2026neutral

The Motley Fool compared AbbVie and Bristol-Myers Squibb as potential investments for 2026, noting AbbVie's resilient revenue growth driven by its next-generation immunology and aesthetics portfolio, while Bristol-Myers Squibb maintains high net margins at a valuation discount.

Why it matters — ABBV watchers would care because the article highlights AbbVie's growth drivers in immunology and aesthetics as key strengths against a competitor.

FAQ

Frequently asked questions about ABBV stock

What is the ABBV stock price forecast for 2026-2027?

The 31 Wall Street analysts covering AbbVie, Inc. have a median 12-month price target of $280, with estimates ranging from $200 to $328. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ABBV stock a buy right now?

Of the 31 analysts covering AbbVie, Inc., 25 rate it a Buy, 5 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks AbbVie, Inc. 96 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ABBV?

As at 22 Aug 2026, AbbVie, Inc. ranks 96 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (100 of 100).

Will ABBV stock go up?

No one can know that. What the data says: the median 12-month target from 31 analysts implies +5.7% from the last close, and Ticker Nerd's factor model ranks AbbVie, Inc. 96 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ABBV stock forecast for 2030?

No analyst covering AbbVie, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ABBV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $200 to $328 over the next 12 months.

How has ABBV stock performed over the past year?

AbbVie, Inc. returned +30.4% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does AbbVie, Inc. do?

AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines and therapies for complex and serious diseases.

What is the latest news on ABBV?

The most recent item we track (PRNewsWire, 21 Aug 2026): "AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline". AbbVie announced it will present new clinical data at the 2026 World Conference on Lung Cancer (WCLC), including an oral presentation of its ABBV-1480 (RC148) PD-1/VEGF bispecific antibody in frontline non-small cell lung cancer, along with updates from its telisotuzumab adizutecan (Temab-A) and ABBV-706 programs across NSCLC and small cell lung cancer.

Company

About AbbVie, Inc.

AbbVie Inc. is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing medicines and therapies for complex and serious diseases. AbbVie’s current portfolio spans immunology, oncology, neuroscience, eye care, and aesthetics, with additional products in virology, gastroenterology, and other specialty areas. The company serves patients through prescription medicines and advanced therapies used in rheumatology, dermatology, gastroenterology, blood cancers, migraine, psychiatric disorders, eye conditions, and certain chronic infectious diseases. AbbVie also markets products through its Allergan Aesthetics business, giving it a presence in both therapeutic healthcare and medical aesthetics. Headquartered in North Chicago, Illinois, AbbVie plays a significant role in the global pharmaceutical market by combining research, manufacturing, and commercialization across multiple high-value specialty segments.

CEO Mr. Robert A. Michael CPA · 57,000 employees · United States · https://www.abbvie.com